Symbols / AGIO
AGIO Chart
About
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.67B |
| Enterprise Value | 857.42M | Income | -412.78M | Sales | 54.03M |
| Book/sh | 20.41 | Cash/sh | 14.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | 539 | IPO | — |
| P/E | — | Forward P/E | -5.77 | PEG | — |
| P/S | 30.94 | P/B | 1.40 | P/C | — |
| EV/EBITDA | -1.84 | EV/Sales | 15.87 | Quick Ratio | 10.53 |
| Current Ratio | 11.46 | Debt/Eq | 3.37 | LT Debt/Eq | — |
| EPS (ttm) | -7.12 | EPS next Y | -4.95 | EPS Growth | — |
| Revenue Growth | 86.10% | Earnings | 2026-04-30 | ROA | -19.93% |
| ROE | -30.20% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -6.09% | Profit Margin | 0.00% | Shs Outstand | 58.59M |
| Shs Float | 49.32M | Short Float | 10.87% | Short Ratio | 7.06 |
| Short Interest | — | 52W High | 46.00 | 52W Low | 22.24 |
| Beta | 0.88 | Avg Volume | 1.13M | Volume | 779.69K |
| Target Price | $39.88 | Recom | Buy | Prev Close | $27.47 |
| Price | $28.53 | Change | 3.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$39.88
Mean price target
2. Current target
$28.53
Latest analyst target
3. DCF / Fair value
$-82.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.53
Low
$28.00
High
$65.00
Mean
$39.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Citigroup | Buy → Buy | $46 |
| 2026-02-12 | main | HC Wainwright & Co. | Buy → Buy | $65 |
| 2026-01-06 | main | JP Morgan | Neutral → Neutral | $25 |
| 2025-12-26 | main | Leerink Partners | Outperform → Outperform | $40 |
| 2025-12-24 | main | Truist Securities | Buy → Buy | $38 |
| 2025-12-24 | main | B of A Securities | Buy → Buy | $34 |
| 2025-12-24 | main | HC Wainwright & Co. | Buy → Buy | $62 |
| 2025-11-26 | init | Citigroup | — → Buy | $38 |
| 2025-11-24 | init | Truist Securities | — → Buy | $32 |
| 2025-11-21 | main | JP Morgan | Neutral → Neutral | $20 |
| 2025-11-20 | down | RBC Capital | Outperform → Sector Perform | $28 |
| 2025-11-20 | main | B of A Securities | Buy → Buy | $32 |
| 2025-11-20 | up | Leerink Partners | Market Perform → Outperform | $34 |
| 2025-11-20 | main | Goldman Sachs | Neutral → Neutral | $25 |
| 2025-11-20 | main | HC Wainwright & Co. | Buy → Buy | $48 |
| 2025-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $56 |
| 2025-07-28 | main | Scotiabank | Sector Outperform → Sector Outperform | $65 |
| 2025-07-22 | main | B of A Securities | Buy → Buy | $51 |
| 2025-05-02 | main | Scotiabank | Sector Outperform → Sector Outperform | $71 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $58 |
- Agios Pharmaceuticals: Worthy Of Accumulation (NASDAQ:AGIO) - Seeking Alpha Mon, 09 Mar 2026 15
- What sentiment indicators say about AGIO stock - July 2025 Catalysts & Low Risk High Reward Ideas - Naître et grandir Sat, 07 Mar 2026 08
- Why (AGIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily Fri, 06 Mar 2026 04
- Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug - simplywall.st Wed, 04 Mar 2026 10
- Top Agios Pharma Executive Makes Notable Insider Move With Recent Stock Sale - TipRanks Fri, 06 Mar 2026 02
- AGIO: Citigroup Raises Price Target Amidst Continuous Buy Ratings | AGIO Stock News - GuruFocus hu, 05 Mar 2026 20
- UAE approves only treatment option for adults with thalassemia - Stock Titan Mon, 02 Mar 2026 12
- This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily Wed, 19 Nov 2025 08
- Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO - Morningstar Wed, 04 Mar 2026 14
- AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - Yahoo Finance hu, 20 Nov 2025 08
- Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug - Sahm Wed, 04 Mar 2026 08
- Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - The Motley Fool ue, 17 Feb 2026 08
- Agios Pharmaceuticals stock tumbles after mixed sickle cell trial results - Investing.com Wed, 19 Nov 2025 08
- Understanding Momentum Shifts in (AGIO) - Stock Traders Daily Mon, 23 Feb 2026 08
- AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia - Yahoo Finance Fri, 05 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5272 | 152255.0 | — | Sale at price 28.88 per share. | WASHBURN THEODORE JAMES JR | Officer | — | 2026-03-03 00:00:00 | D |
| 1 | 18055 | 522873.0 | — | Sale at price 28.96 per share. | GOFF BRIAN | Chief Executive Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 5035 | 145814.0 | — | Sale at price 28.96 per share. | JONES CECILIA | Chief Financial Officer | — | 2026-03-02 00:00:00 | D |
| 3 | 2223 | 64378.0 | — | Sale at price 28.96 per share. | WASHBURN THEODORE JAMES JR | Officer | — | 2026-03-02 00:00:00 | D |
| 4 | 4055 | 117433.0 | — | Sale at price 28.96 per share. | GHEUENS SARAH | Officer | — | 2026-03-02 00:00:00 | D |
| 5 | 5218 | 151113.0 | — | Sale at price 28.96 per share. | BURNS JAMES WILLIAM | Officer | — | 2026-03-02 00:00:00 | D |
| 6 | 2868 | 83057.0 | — | Sale at price 28.96 per share. | MILANOVA TSVETA | Officer | — | 2026-03-02 00:00:00 | D |
| 7 | 17586 | nan | — | — | BURNS JAMES WILLIAM | Officer | — | 2026-03-02 00:00:00 | D |
| 8 | 9666 | nan | — | — | MILANOVA TSVETA | Officer | — | 2026-03-02 00:00:00 | D |
| 9 | 16969 | nan | — | — | JONES CECILIA | Chief Financial Officer | — | 2026-03-02 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 67.12M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.06 | 0.00 | 0.00 |
| NormalizedEBITDA | -466.95M | -1.51B | -384.86M | -518.19M |
| TotalUnusualItems | 0.00 | 1.09B | 0.00 | 137.70M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 1.09B | 0.00 | 137.70M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -412.78M | 673.73M | -352.09M | -231.80M |
| ReconciledDepreciation | 5.18M | 5.65M | 6.62M | 8.56M |
| ReconciledCostOfRevenue | 6.34M | 4.17M | 2.88M | 1.70M |
| EBITDA | -466.95M | -420.08M | -384.86M | -380.48M |
| EBIT | -472.13M | -425.74M | -391.49M | -389.05M |
| NetInterestIncome | 56.38M | 48.08M | 33.34M | 12.79M |
| InterestIncome | 56.38M | 48.08M | 33.34M | 12.79M |
| NormalizedIncome | -412.78M | -348.29M | -352.09M | -369.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -412.78M | 673.73M | -352.09M | -231.80M |
| TotalExpenses | 526.16M | 462.24M | 418.31M | 403.29M |
| TotalOperatingIncomeAsReported | -472.13M | -425.74M | -391.49M | -389.05M |
| DilutedAverageShares | 57.97M | 57.89M | 55.65M | 54.79M |
| BasicAverageShares | 57.97M | 56.81M | 55.65M | 54.79M |
| DilutedEPS | -7.12 | 11.64 | -6.33 | -4.23 |
| BasicEPS | -7.12 | 11.86 | -6.33 | -4.23 |
| DilutedNIAvailtoComStockholders | -412.78M | 673.73M | -352.09M | -231.80M |
| NetIncomeCommonStockholders | -412.78M | 673.73M | -352.09M | -231.80M |
| NetIncome | -412.78M | 673.73M | -352.09M | -231.80M |
| NetIncomeIncludingNoncontrollingInterests | -412.78M | 673.73M | -352.09M | -231.80M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | 1.96B | |
| NetIncomeContinuousOperations | -412.78M | 673.73M | -352.09M | -231.80M |
| TaxProvision | -1.02M | 44.24M | 0.00 | 0.00 |
| PretaxIncome | -413.80M | 717.97M | -352.09M | -231.80M |
| OtherIncomeExpense | 1.96M | 1.10B | 6.05M | 144.45M |
| OtherNonOperatingIncomeExpenses | 1.96M | 6.49M | 6.05M | 6.75M |
| SpecialIncomeCharges | 0.00 | 1.09B | 0.00 | 137.70M |
| GainOnSaleOfBusiness | 0.00 | 1.09B | 0.00 | 137.70M |
| RestructuringAndMergernAcquisition | -127.85M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 56.38M | 48.08M | 33.34M | 12.79M |
| TotalOtherFinanceCost | -12.79M | -836.00K | ||
| InterestIncomeNonOperating | 56.38M | 48.08M | 33.34M | 12.79M |
| OperatingIncome | -472.13M | -425.74M | -391.49M | -389.05M |
| OperatingExpense | 519.82M | 458.07M | 415.43M | 401.58M |
| ResearchAndDevelopment | 339.54M | 301.29M | 295.53M | 279.91M |
| SellingGeneralAndAdministration | 180.28M | 156.78M | 119.90M | 121.67M |
| GrossProfit | 47.68M | 32.33M | 23.94M | 12.54M |
| CostOfRevenue | 6.34M | 4.17M | 2.88M | 1.70M |
| TotalRevenue | 54.03M | 36.50M | 26.82M | 14.24M |
| OperatingRevenue | 54.03M | 36.50M | 26.82M | 14.24M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 16.22M | 16.22M | 16.22M | 16.22M |
| OrdinarySharesNumber | 58.45M | 57.16M | 55.95M | 55.04M |
| ShareIssued | 74.67M | 73.37M | 72.16M | 71.26M |
| TotalDebt | 40.21M | 56.99M | 72.00M | 85.66M |
| TangibleBookValue | 1.19B | 1.54B | 811.02M | 1.10B |
| InvestedCapital | 1.19B | 1.54B | 811.02M | 1.10B |
| WorkingCapital | 859.85M | 884.44M | 765.88M | 770.14M |
| NetTangibleAssets | 1.19B | 1.54B | 811.02M | 1.10B |
| CapitalLeaseObligations | 40.21M | 56.99M | 72.00M | 85.66M |
| CommonStockEquity | 1.19B | 1.54B | 811.02M | 1.10B |
| TotalCapitalization | 1.19B | 1.54B | 811.02M | 1.10B |
| TotalEquityGrossMinorityInterest | 1.19B | 1.54B | 811.02M | 1.10B |
| StockholdersEquity | 1.19B | 1.54B | 811.02M | 1.10B |
| GainsLossesNotAffectingRetainedEarnings | 2.19M | -1.52M | -441.00K | -12.54M |
| OtherEquityAdjustments | 2.19M | -1.52M | -441.00K | -12.54M |
| TreasuryStock | 802.49M | 802.49M | 802.49M | 802.49M |
| RetainedEarnings | -561.71M | -148.92M | -822.65M | -470.56M |
| AdditionalPaidInCapital | 2.56B | 2.49B | 2.44B | 2.39B |
| CapitalStock | 75.00K | 73.00K | 72.00K | 71.00K |
| CommonStock | 75.00K | 73.00K | 72.00K | 71.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 104.11M | 122.24M | 126.10M | 137.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.91M | 41.09M | 58.14M | 75.28M |
| OtherNonCurrentLiabilities | 90.00K | 880.00K | 1.16M | 3.28M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 21.82M | 40.21M | 56.99M | 72.00M |
| LongTermCapitalLeaseObligation | 21.82M | 40.21M | 56.99M | 72.00M |
| CurrentLiabilities | 82.21M | 81.16M | 67.95M | 62.63M |
| CurrentDebtAndCapitalLeaseObligation | 18.39M | 16.78M | 15.01M | 13.66M |
| CurrentCapitalLeaseObligation | 18.39M | 16.78M | 15.01M | 13.66M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 27.26M | 29.93M | 23.23M | 18.11M |
| PayablesAndAccruedExpenses | 36.55M | 34.44M | 29.71M | 30.86M |
| CurrentAccruedExpenses | 18.20M | 16.93M | 19.93M | 12.24M |
| Payables | 18.36M | 17.51M | 9.78M | 18.62M |
| TotalTaxPayable | 0.00 | 871.00K | 0.00 | |
| IncomeTaxPayable | 0.00 | 871.00K | 0.00 | |
| AccountsPayable | 18.36M | 16.64M | 9.78M | 18.62M |
| TotalAssets | 1.30B | 1.66B | 937.12M | 1.24B |
| TotalNonCurrentAssets | 355.17M | 697.60M | 103.28M | 405.95M |
| OtherNonCurrentAssets | 3.93M | 4.72M | 4.06M | 3.96M |
| InvestmentsAndAdvances | 310.01M | 638.32M | 29.43M | 313.87M |
| InvestmentinFinancialAssets | 310.01M | 638.32M | 29.43M | 313.87M |
| AvailableForSaleSecurities | 310.01M | 638.32M | 29.43M | 313.87M |
| NetPPE | 41.23M | 54.55M | 69.79M | 88.12M |
| AccumulatedDepreciation | -60.12M | -56.50M | -52.23M | -50.07M |
| GrossPPE | 101.34M | 111.05M | 122.02M | 138.19M |
| Leases | 37.52M | 37.52M | 37.28M | 37.28M |
| ConstructionInProgress | 2.75M | 897.00K | 608.00K | 657.00K |
| OtherProperties | 17.57M | 17.53M | 17.43M | 23.18M |
| MachineryFurnitureEquipment | 13.06M | 12.23M | 12.29M | 11.94M |
| BuildingsAndImprovements | 30.45M | 42.88M | 54.41M | 65.13M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 942.05M | 965.60M | 833.84M | 832.77M |
| OtherCurrentAssets | 44.13M | 40.16M | 35.02M | 38.95M |
| AssetsHeldForSaleCurrent | 0.00 | |||
| PrepaidAssets | 39.84M | |||
| Inventory | 32.92M | 27.62M | 19.08M | 8.49M |
| FinishedGoods | 2.58M | 3.02M | 1.46M | 942.00K |
| WorkInProcess | 30.25M | 24.51M | 17.57M | 7.55M |
| RawMaterials | 88.00K | 89.00K | 51.00K | 0.00 |
| Receivables | 10.58M | 4.11M | 2.81M | 2.21M |
| OtherReceivables | 4.38M | |||
| AccountsReceivable | 10.58M | 4.11M | 2.81M | 2.21M |
| CashCashEquivalentsAndShortTermInvestments | 854.42M | 893.71M | 776.93M | 783.12M |
| OtherShortTermInvestments | 765.29M | 817.46M | 688.72M | 643.86M |
| CashAndCashEquivalents | 89.13M | 76.25M | 88.20M | 139.26M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -387.29M | -391.53M | -314.56M | -314.36M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -802.49M | |
| RepaymentOfDebt | 0.00 | 0.00 | -331.00K | -578.00K |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -14.32M | -1.69M | -18.50M | -4.88M |
| IncomeTaxPaidSupplementalData | 628.00K | 43.15M | 1.57M | 0.00 |
| EndCashPosition | 89.13M | 76.25M | 88.20M | 139.26M |
| BeginningCashPosition | 76.25M | 88.20M | 139.26M | 203.13M |
| ChangesInCash | 12.88M | -11.96M | -51.05M | -63.87M |
| FinancingCashFlow | 8.68M | 14.44M | 5.43M | 2.35M |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingFinancingActivities | 8.68M | 14.44M | 5.43M | 2.35M |
| ProceedsFromStockOptionExercised | 8.68M | 14.44M | 5.43M | 2.68M |
| NetCommonStockIssuance | 0.00 | 0.00 | -802.49M | |
| CommonStockPayments | 0.00 | 0.00 | -802.49M | |
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -331.00K | -578.00K |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -331.00K | -578.00K |
| LongTermDebtPayments | 0.00 | 0.00 | -331.00K | -578.00K |
| InvestingCashFlow | 377.18M | 363.44M | 239.57M | 243.26M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | 1.80B | |
| CashFlowFromContinuingInvestingActivities | 377.18M | 363.44M | 239.57M | 243.26M |
| NetOtherInvestingChanges | 131.78M | |||
| NetInvestmentPurchaseAndSale | 391.50M | -724.05M | 256.75M | 115.39M |
| SaleOfInvestment | 1.03B | 818.38M | 674.68M | 1.15B |
| PurchaseOfInvestment | -641.76M | -1.54B | -417.93M | -1.03B |
| NetBusinessPurchaseAndSale | 0.00 | 1.09B | 0.00 | 131.78M |
| SaleOfBusiness | 0.00 | 1.09B | 0.00 | 131.78M |
| NetIntangiblesPurchaseAndSale | -10.00M | 0.00 | -17.50M | 0.00 |
| PurchaseOfIntangibles | -10.00M | 0.00 | -17.50M | 0.00 |
| NetPPEPurchaseAndSale | -4.32M | -1.65M | 326.00K | -3.92M |
| SaleOfPPE | 0.00 | 40.00K | 1.32M | 964.00K |
| PurchaseOfPPE | -4.32M | -1.69M | -999.00K | -4.88M |
| OperatingCashFlow | -372.98M | -389.84M | -296.06M | -309.48M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | -93.23M | |
| CashFlowFromContinuingOperatingActivities | -372.98M | -389.84M | -296.06M | -309.48M |
| ChangeInWorkingCapital | -33.04M | -19.77M | -19.06M | -16.43M |
| ChangeInOtherCurrentLiabilities | -17.57M | -15.28M | -15.79M | -7.83M |
| ChangeInPayablesAndAccruedExpense | -527.00K | 11.17M | 4.08M | 1.82M |
| ChangeInAccruedExpense | -1.40M | 3.69M | 12.82M | -1.62M |
| ChangeInPayable | 875.00K | 7.47M | -8.73M | 3.44M |
| ChangeInAccountPayable | 1.75M | 6.60M | -8.73M | 3.44M |
| ChangeInTaxPayable | -871.00K | 871.00K | 0.00 | 0.00 |
| ChangeInIncomeTaxPayable | -871.00K | 871.00K | 0.00 | 0.00 |
| ChangeInPrepaidAssets | -3.17M | -5.81M | 3.83M | -176.00K |
| ChangeInInventory | -5.30M | -8.54M | -10.58M | -8.49M |
| ChangeInReceivables | -6.47M | -1.30M | -604.00K | -1.76M |
| ChangesInAccountReceivables | -6.47M | -1.30M | -604.00K | -2.21M |
| OtherNonCashItems | 22.43M | -877.61M | 28.22M | -117.86M |
| StockBasedCompensation | 52.55M | 42.85M | 44.77M | 49.30M |
| AmortizationOfSecurities | -7.20M | -14.49M | -5.05M | -1.20M |
| DepreciationAmortizationDepletion | 5.18M | 5.65M | 6.62M | 8.56M |
| DepreciationAndAmortization | 5.18M | 5.65M | 6.62M | 8.56M |
| OperatingGainsLosses | -113.00K | -200.21M | 525.00K | -48.00K |
| GainLossOnInvestmentSecurities | -118.00K | -167.00K | -28.00K | |
| GainLossOnSaleOfPPE | 5.00K | -39.00K | 553.00K | -48.00K |
| GainLossOnSaleOfBusiness | 0.00 | -200.00M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -412.78M | 673.73M | -352.09M | -231.80M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AGIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|